Begin main content

Radioembolization with yttrium-90 Microspheres for the Management of Uveal Melanoma Liver Metastases: A Review of Clinical Effectiveness and Cost-Effectiveness

Last updated: August 30, 2018
Project Number: RC1008-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report

Question

  1. What is the clinical effectiveness of radioembolization with yittrium-90 microspheres for the management of uveal melanoma liver metastases?
  2. What is the cost-effectiveness of radioembolization with yittrium-90 microspheres versus other management options for the management of uveal melanoma liver metastases?

Key Message

One retrospective study on patients with uveal melanoma liver metastasis compared the clinical effectiveness and toxicity of SIRT using yttrium-90 microspheres to a historical control group using systemic chemotherapy. Patients on SIRT both as first-line therapy or following failed systemic chemotherapy - had a statistically significant improvement in median overall survival time compared to those on historical systemic chemotherapy, and this effect was larger in the group of patients who received SIRT as first-line treatment. Most treatment-related side effects on patients with SIRT were mild and self-limited, and were more pronounced in patients with systemic chemotherapy. These findings from limited evidence need to be treated cautiously. There was no relevant evidence found on the cost-effectiveness of radioembolization with yittrium-90 microspheres versus other management options for the management of uveal melanoma liver metastases.